Patient Compensation Fund May Be Answer To Liability Worries, Breaux Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Creating a central fund for patient injury compensation could help shield Rx and OTC drug manufacturers from substantial product liability, the former senator says at the Consumer Healthcare Products Association’s annual meeting.
You may also be interested in...
Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?
The Greatest FDA Advisory Committees, Part III: The Power of The Patients
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.
The Greatest FDA Advisory Committees, Part II: The Birth Of The ‘Pazdur Moment’
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: